Darshana is a Founder and Managing Partner of Catalyst Health Ventures (CHV). She is actively involved in all aspects of fund management including investments and capital raising and has led several investments in the medical device, women’s health and diagnostics markets.
She led CHV’s investments in Augmenix (acquired by Boston Scientific), nVision Medical (acquired by Boston Scientific), Maxwell Health (acquired by SunLife), Aria CV, PanTher Therapeutics, AtaCor Medical, Instylla, and Avive. She currently (or previously) represents CHV on the Boards of all companies.
Prior to joining CHV in 2007, Darshana was an Investigator at Vertex Pharmaceuticals, and an integral part of drug development programs in oncology, metabolic disease, and immunology. Previously she worked at Genome Therapeutics, a Massachusetts-based biotechnology company and at the Dana Farber Cancer Institute and completed an internship at the United Nations. She has authored several publications and scientific journal articles. Darshana currently serves as an advisor of the Deshpande Center for Technological Innovation at MIT, (a foundation that helps MIT students and faculty commercialize breakthrough technologies and inventions), as a Board Director of Tie Boston (Boston chapter of The Indus Valley Entrepreneurs), and as a lead advisor to the Portfolia FemTech fund (an investment fund designed for women). She also serves on the Board of Advisors of MedExec Women and serves on the investment committee of Amplify (an investment fund of the MassGeneral Brigham network).
Darshana received an M.P.A. from Harvard University, an M.A. in Cell and Molecular Biology from Boston University, and a B.S. in Biochemistry from Bombay University in Bombay, India.